Biogen

See the following -

How Google Plans to Reinvent Healthcare

Cheryl Swanson | The Motley Fool | September 3, 2016

Glucose-monitoring contact lenses for diabetics, wrist computers that read diagnostic nanoparticles injected in the blood stream, implantable devices that modify electrical signals that pass along nerves, medication robots, human augmentation, human brain simulation -- the list goes on. That's not an inventory of improbable CGI effects from the latest sci-fi movie, it's a list of initiatives being tackled by Alphabet's Google Life Sciences research unit, recently rebranded Verily...

Read More »

Mylan Isn't Alone: 11 Drugmakers with Off-the-Charts Pricing Power

Matt Krantz | USA Today | August 25, 2016

Mylan (MYL) is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. Gilead (GILD), Biogen (BIIB) and Amgen (AMGN), along with eight other drug giants in the Standard & Poor's 500, enjoyed off-the-charts pricing power on their products relative to costs — far beyond Mylan's, according to a USA TODAY analysis of data from S&P Global Market Intelligence...

Read More »

Open Targets: New Name, New Data

Press Release | Wellcome Trust Sanger Institute, European Bioinformatics Institute | April 19, 2016

Following the successful launch of its Target Validation platform at the end of 2015, the Centre for Therapeutic Target Validation has released its first open experimental datasets. Now renamed Open Targets, the pioneering public–private initiative remains committed to speeding up the discovery of new medicines. Open Targets projects use genome-scale experiments and analysis to provide evidence on the biological validity of therapeutic targets – and to glean insights into the likely effectiveness of pharmacological intervention on these targets...

Read More »

Vibrent Health Joins Europe’s Open Source RADAR-CNS Program to Develop Scalable Analytics Platform for Health Wearables

Press Release | Vibrent Health, RADAR-CNS | April 24, 2018

Health technology company Vibrent Health...expands its digital health solutions business into Europe through a partnership with Remote Assessment of Disease and Relapse – Central Nervous System (RADAR-CNS). Vibrent Health will work with the Europe-led consortium on developing digital health programs featuring predictive analytics designed to monitor and help improve treatment for depression, multiple sclerosis, and epilepsy. RADAR-CNS is conducting research using a range of medical-grade sensors, such as electro-cardiograms, as well as a growing portfolio of consumer-grade sensors, including accelerometers and smartphone applications, that collect participant data from surveys and smartphone sensors.

Read More »